Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little ...Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.展开更多
目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia...目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia”为关键词在数据库中获取疾病靶点,通过Venny 2.1得到药物和疾病的共同靶点,从而构建中药有效成分靶点-疾病靶点网络。使用STRING数据库构建核心基因蛋白质-蛋白质相互作用网络。在Metascap数据库进行疾病与药物交集靶点的基因本体论(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。最后通过“Autodock”软件对核心活性成分和核心靶点进行分子对接验证。结果:筛选得到免怀散的有效成分27个、核心靶点176个及疾病靶点228个,GO功能富集分析显示交集靶点参与了生物过程、细胞组分、分子功能等共715个生物功能条目;KEGG通路富集分析收集到113条通路,主要包括癌症通路、化学致癌作用-受体激活、酪氨酸蛋白激酶(Janus-activated Kinase,JAK)-信号转导和转录激活因子(Signal Transducer and Activator of Transcription,STAT)信号通路、癌症中的蛋白聚糖、乳腺癌、磷脂酰肌醇3激酶(Phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(Akt)信号通路、T细胞受体信号通路等。分子对接的结合能均小于-5 kcal/mol,分子对接结果良好。结论:免怀散可通过多成分、多靶点、多通路发挥治疗HPRL的作用,为临床应用免怀散治疗HPRL提供了一定的理论依据。展开更多
BACKGROUND Pituitary metastasis is an uncommon manifestation of systemic malignant tumors.Moreover,hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare.CA...BACKGROUND Pituitary metastasis is an uncommon manifestation of systemic malignant tumors.Moreover,hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare.CASE SUMMARY A 53-year-old male patient was admitted to our hospital with complaints of bilateral blurred vision,dizziness,polyuria,nocturia,severe fatigue and somnolence,decreased libido,and intermittent nausea and vomiting for more than 6 mo.During the last 7 d,the dizziness had worsened.Laboratory investigations revealed overall hypofunction of the pituitary gland,but the patient had an elevated serum prolactin level(703.35 mg/mL).Preoperative magnetic resonance imaging revealed a tumor in the sellar region,accompanied by intratumoral hemorrhage and calcification.Thus,transnasal subtotal resection of the lesion in the sellar region was performed.The histopathological and immunohistochemical examinations of the resected lesion revealed metastasis of lung adenocarcinoma to the pituitary gland.Oral hydrocortisone(30 mg/d)and levothyroxine(25 mg/d)were given both pre-and postoperatively.Postoperatively,the clinical symptoms were significantly improved.However,4 mo following the surgery,the patient succumbed due to multiple organ failure.CONCLUSION Hyperprolactinemia is one of the markers of poor prognosis in patients with carcinoma that metastasizes to the pituitary gland.Exogenous hormone supplementation plays a positive role in relieving the symptoms of patients and improving quality of life.展开更多
文摘Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.
文摘目的:采用网络药理学和分子对接技术预测免怀散治疗高泌乳素血症(Hyperprolactinemia,HPRL)的作用靶点,并探讨其治疗HPRL的潜在作用机制和有效物质。方法:通过数据库获取免怀散的潜在活性成分及其药物靶点,并且以“Hyperprolactinemia”为关键词在数据库中获取疾病靶点,通过Venny 2.1得到药物和疾病的共同靶点,从而构建中药有效成分靶点-疾病靶点网络。使用STRING数据库构建核心基因蛋白质-蛋白质相互作用网络。在Metascap数据库进行疾病与药物交集靶点的基因本体论(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。最后通过“Autodock”软件对核心活性成分和核心靶点进行分子对接验证。结果:筛选得到免怀散的有效成分27个、核心靶点176个及疾病靶点228个,GO功能富集分析显示交集靶点参与了生物过程、细胞组分、分子功能等共715个生物功能条目;KEGG通路富集分析收集到113条通路,主要包括癌症通路、化学致癌作用-受体激活、酪氨酸蛋白激酶(Janus-activated Kinase,JAK)-信号转导和转录激活因子(Signal Transducer and Activator of Transcription,STAT)信号通路、癌症中的蛋白聚糖、乳腺癌、磷脂酰肌醇3激酶(Phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(Akt)信号通路、T细胞受体信号通路等。分子对接的结合能均小于-5 kcal/mol,分子对接结果良好。结论:免怀散可通过多成分、多靶点、多通路发挥治疗HPRL的作用,为临床应用免怀散治疗HPRL提供了一定的理论依据。
文摘BACKGROUND Pituitary metastasis is an uncommon manifestation of systemic malignant tumors.Moreover,hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare.CASE SUMMARY A 53-year-old male patient was admitted to our hospital with complaints of bilateral blurred vision,dizziness,polyuria,nocturia,severe fatigue and somnolence,decreased libido,and intermittent nausea and vomiting for more than 6 mo.During the last 7 d,the dizziness had worsened.Laboratory investigations revealed overall hypofunction of the pituitary gland,but the patient had an elevated serum prolactin level(703.35 mg/mL).Preoperative magnetic resonance imaging revealed a tumor in the sellar region,accompanied by intratumoral hemorrhage and calcification.Thus,transnasal subtotal resection of the lesion in the sellar region was performed.The histopathological and immunohistochemical examinations of the resected lesion revealed metastasis of lung adenocarcinoma to the pituitary gland.Oral hydrocortisone(30 mg/d)and levothyroxine(25 mg/d)were given both pre-and postoperatively.Postoperatively,the clinical symptoms were significantly improved.However,4 mo following the surgery,the patient succumbed due to multiple organ failure.CONCLUSION Hyperprolactinemia is one of the markers of poor prognosis in patients with carcinoma that metastasizes to the pituitary gland.Exogenous hormone supplementation plays a positive role in relieving the symptoms of patients and improving quality of life.
